SEATTLE (May 31, 2022) – Seattle Cancer Care Alliance, now Fred Hutchinson Cancer Center, the only National Cancer Institute (NCI)-designated cancer center in Washington, will have more than 20 clinicians presenting at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7, 2022 in Chicago.
Presentations cover a broad range of cancer care topics, from prevention to treatment, and will highlight results from trials in prostate, breast, skin and hematologic cancers. Clinical researchers are also participating in discussions that highlight our organization’s leadership in the multidisciplinary approach to care, cancer survivorship and health equity.
“The work our physician-researchers are sharing this year further demonstrate their unyielding commitment to improving oncology care for every patient,” said Nancy Davidson, MD, Executive Vice President, Clinical Affairs Senior Vice President, Clinical Research Division. “We’re all looking forward to joining the clinical oncology community in person this year and contributing to the collective discoveries advancing cancer care and improving outcomes.”
More information about clinicians’ presentations and publications at ASCO is available at: https://www.seattlecca.org/conference/asco-2022
Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).
Author: Petros Grivas, MD, PhD
The Power of a Multispecialty Approach (Moderator and Medical Oncology Perspective.
Author: Petros Grivas, MD, PhD
Real-world practice patterns in the diagnosis of recurrent metastatic breast cancer in Washington state
Author: Poorni Manohar, MD
The relationship between chronic health conditions and employment transitions among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
Author: Neel S. Bhatt MBBS, MPH
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Author: Evan Y. Yu MD
Matched FES and FDG PET imaging in patients with hormone receptor-positive, HER2+ advanced breast cancer.
Author: Natasha Hunter MD
Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.
Author: Ryan Lynch MD
Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.
Author: Ryan Lynch MD
Peripheral blood T-cell receptor repertoire profiling of advanced non-small cell lung cancer patients receiving PD-1/PD-L1 treatment.
Author: Diane Tseng PhD, MD
SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).
Author: David Bing Zhen, MD
CD20: Old Target, New Approach for Lymphoma.
Author: Brian G. Till, MD
Rare and Vulnerable Patient Populations in Skin Cancer: A Work in Progress.
Author: Shailender Bhatia, MD
Overcoming Socioeconomic and Geographic Barriers to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: How Do We Widen Access Globally?
Author: Jerald Radich, MD
T-Cell Engagers for Prostate Cancer: Efficacy and Toxicity Management.
Author: Michael Thomas Schweizer, MD
In It for the Long Haul: Outcomes in Hormone Receptor–Positive Breast Cancer.
Author: Nancy E. Davidson, MD, FASCO
Making Sense of Frontline Maintenance Options for Patients With Homologous Repair Proficient Disease.
Author: Elizabeth M. Swisher, MD
Dissecting Racial Disparities in Endometrial Cancer.
Author: Kemi Morenikeji Doll, MD
AR and PARP: Partners in Crime.
Author: Heather H. Cheng, MD, PhD
Rethinking "Cis"-temic Radiosensitizers.
Author: Cristina P. Rodriguez, MD
Rates of germline genetic testing and DNA damage response mutations found through population-based recruitment of men with incident metastatic prostate cancer.
Author: Hiba Khan, MD, MPH (Fellow)
Maximizing Remission in Ovarian Cancer.
Author: Barbara Norquist, MD
Asparaginase: A COG in the Wheel of Pediatric ALL?
Author: Ryan Daniel Cassaday, MD
Highlights of Health Services Research and Quality Improvement Track.
Author: Veena Shankaran, MD, MS
Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
Author: David Bing Zhen, MD (Second author)
About Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center is an independent, nonprofit, unified adult cancer care and research center that is clinically integrated with UW Medicine, a world leader in clinical care, research and learning. Fred Hutchinson Cancer Center was created in April 2022 by the merger of longtime partners, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance. Together, our fully integrated research and clinical care teams seek to discover new cures for the world’s deadliest diseases and make life beyond cancer a reality.
The first National Cancer Institute-designated cancer center in the Pacific Northwest, Fred Hutch is a global leader in bone marrow transplantation, HIV/AIDS, immunotherapy and COVID-19, confirming our reputation as one of the world’s leading cancer, infectious disease and biomedical research centers. Based in Seattle, Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and has network affiliations with hospitals in five states.
Heather Platisha, firstname.lastname@example.org or (415) 676-8030